Panel Discussion: AI, talent and technology: The new FR&D toolkit

Panellists in this video:
Dr Tushar N Mehta, VP – Respiratory and Advanced Analytical R&D, Amneal Pharmaceuticals (MODERATOR)
Mr Nilesh Malaviya, Head – Formulation Development, Alembic Pharmaceuticals
Dr Sanju Dhawan, Sr Director GPRD & Site Leader, Baxter Pharmaceuticals India
Dr Dhaval Pethani, Co-Founder and CTO, Cutyx Research LLP
Dr Prabhat Shrivastava, Associate Director and Vertical Head (Formulation and Packaging Development), Piramal Pharma Solutions, Ahmedabad
Dr Vinod Venkatpurwar, Sr GM, Formulation Development, Cadila Pharmaceuticals
Dr Ajay Vairale, Sr GM, Cadila Pharmaceuticals
Dr Sunny P Desai, Sr Manager (Site Lead) – MS&T (Technology Transfer), Zydus Lifesciences

Key Highlights:
[1] AI is transforming formulation development from trial-and-error to predict-and-design, enabling faster, smarter decisions.

[2] Manufacturability and scale-up must be built into product development from the pre-formulation stage, not addressed at the end.

[3] Digital twins, AI models and electronic lab notebooks can reduce scale-up failures, eliminate repetitive work and speed up technology transfer.

[4] AI is only as powerful as the quality of the data behind it. A strong digital foundation is the first step towards successful AI adoption.

[5] The real value of AI lies in rethinking systems, with connected data, traceable workflows and integrated digital processes.

[6] AI should augment, not replace scientists. Human expertise, judgement and accountability remain central to every development decision.

[7] Successful AI adoption depends on strong governance, ethical use and protecting confidential organisational data.

[8] The future belongs to AI-enabled scientists who understand both the potential and the limitations of AI, and use it to bring medicines to patients faster.

The post Panel Discussion: AI, talent and technology: The new FR&D toolkit appeared first on Express Pharma.